REFERENCES
- Miner WD, Sanger GJ. Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antag-onism. Br J Pharmacol 1986; 88: 497–9.
- Cubeddu LX, Hoffmann IS, Fuenmayor NT, Firm AL. Efficacy of ondansetron (GR 38032 F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990; 322: 810–6.
- Andrews PLR, Davis CJ. The mechanism of emesis induced by anti-cancer therapies. In: Andrews P.L.R., Sanger G J. Eds. Emesis in anti-cancer therapy. Mechanism and treatment. London: Hall Medical 1993; 113-61.
- Marty M on behalf of the Granisetron Study Group. A comparative study of the granisetron, a selective 5-HT3 antag-onist, versus a standard antiemetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic induced emesis. Eur J Cancer 1990: 26: suppl 1, S 28-32.
- Jantunen IT, Flander MK, Heikkinen MI, Kuoppala TA, Teerenhovi L, Kataja VV. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non cisplatin containing chemotherapy. Acta Oncol 1993; 32: 4, 413–5.
- Clavel M, Boneterre J, D'Allens H, Paillarse J M and the French Ondansetron Study Group. Oral ondansetron in the prevention of chemotherapy induced emesis in breast cancer patients. Eur J Cancer 1995; 31 A: 1, 15-9.
- Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimens. Eur Cancer Clin Oncol 1989; 25: suppl. 1, S 35-9.
- Medler EM, Gruben D, Johnsonbaugh RE, Friedman CJ, Peelier P. Acute antiemetic response oral granisetron superior to oral prochlorperazine in patients receiving moder-ately emetogenic chemotherapy. 19h ESMO Congress Lisbon 1994, Extended Abstracts.
- Fetting JH, Grochow LB, Folstein MF et al. The course of nausea and vomiting after high-dose cydophosphamide. Cancer Treat Rep 1982; 60 (7): 1487–93.
- Cubeddu LX, Pendergrass K, Ryan J et al. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol Trials 1994; 17: 137–148.
- Campora E, Oliva C, Mammoliti S, Cetto GL, Fosser V, Marangolo M, Rosso R. Oral ondansetron (GR 38032 F) for the control of CMF-induced emesis in the out patient. Breast Cancer Res Treat 1991; 19: 129–32.
- Campora E, Giudici S, Merlini L, Rosso R. Control of acute and delayed FAC/FEC-induced emesis and GI toxicity at subsequent cycles: a randomized trial of metodopramide, dexamethasone or orphenadrine versus ondansetron and dex-amethasone. Proc Am Soc Clin Oncol 1992; 11: 1358.
- Massidda B, Ionta MT, Scanu A, Foddi MR. Single intravenous bolus dose of 5-HT3-receptor-antagonists in chemotherapy induced emesis. Supportive Care Cancer 1995; 3, (5): 340–1.
- The Italian Group for Antiemetic Research. Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332 (1): 1-5.
- Massidda B, Laconi S, Foddi MR, Salamah K, Ionta MT. Prevention of non-cisplatin induced emesis. Role of the antagonists of 5-HT3-receptors. Ann Oncol 1994; 5, suppl. 8: 204.
- Campora E, Simoni C, Rosso R. Tropisetron verso ondansetron nella prevenzione e controllo dell'emesi in pazi-enti sottoposte a polichemioterapia con FAC/FEC per carci-noma mammario metastatico operato. Min Med 1994; 85: 25–31.
- Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338 (8765): 483–7.
- Koo WH, Ang PT. Randomized controlled study to evaluate the role of oral dexamethasone in prevention of chemotherapy-induced emesis. Proc31st Ann Meet Am Soc Clin Oncol (ASCO) 1995; 14: 531.
- Jones AL, Lee GJ, Bosanquet N. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy induced emesis. Eur J Cancer 1992; 29 A (1): 51-6.